Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11357-11368

  Kawabata, Shigeru ^a   Christine Hollander, M ^b   Munasinghe, Jeeva P ^c   Brinster, Lauren R ^d   Mercado Matos, José R ^b   Li, Jie ^e   Regales, Lucia ^f   Pao, William ^g   Jänne, Pasi A ^h   Wong, Kwok Kin ^h   Butman, John A ^d   Lonser, Russell R ^c   Hansen, Marlan R ⁱ   Gurgel, Richard K ^j   Vortmeyer, Alexander O ^e   Dennis, Phillip A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^j UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Ear tumorigenesis; EGFR; EGFR targeted therapy; Mouse model of adenomatous ear tumor

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUCIN 1; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; PROTEIN KINASE B; SURFACTANT PROTEIN C; THYROID TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EGFR PROTEIN, MOUSE; SFTPC PROTEIN, HUMAN; UTEROGLOBIN;

ADENOCARCINOMA; AGGRESSIVE PAPILLARY MIDDLE EAR TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CELL PROLIFERATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; FEMALE; H1975 CELL; HEAD TILTING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; MIDDLE EAR ADENOCARCINOMA; MIDDLE EAR TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TEMPORAL BONE TUMOR; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME; ADENOMA; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; EAR NEOPLASMS; GENETICS; GENOTYPE; METABOLISM; MIDDLE EAR; MOTOR ACTIVITY; MUTATION; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHENOTYPE; PROMOTER REGION; SIGNAL TRANSDUCTION; SKULL NEOPLASMS; TEMPORAL BONE; TRANSGENIC MOUSE;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BEHAVIOR, ANIMAL; DRUG DESIGN; EAR NEOPLASMS; EAR, MIDDLE; FEMALE; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; MUTATION; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; PROMOTER REGIONS, GENETIC; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKULL NEOPLASMS; TEMPORAL BONE; UTEROGLOBIN; X-RAY MICROTOMOGRAPHY;

EID: 84929613164     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3605     Document Type: Article

References (32)

1. Michaels L, Thompson LDR, Soucek S, Sandison A, Beale T, Henry K and Davis GL. (2005). Tumours of the Ear. In: Barnes L, Eveson JW, Reichart P and Sidransky D, eds. World Health Organization Classification of Tumours Pathology and Genetics of Head and Neck Tumours: IARC Press), pp. 329-360.
2. Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer. 1989;64(11):2292-2302.
3. Tysome JR, Harcourt J, Patel MC, Sandison A and Michaels L. Aggressive papillary tumor of the middle ear: a true entity or an endolymphatic sac neoplasm? Ear Nose Throat J. 2008; 87(7):378-393.
4. Vortmeyer AO, Huang SC, Koch CA, Governale L, Dickerman RD, McKeever PE, Oldfield EH and Zhuang Z. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res. 2000;60(21):5963-5965.
5. Hamazaki S, Yoshida M, Yao M, Nagashima Y, Taguchi K, Nakashima H and Okada S. Mutation of von Hippel-Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor. Hum Pathol. 2001;32(11):1272-1276.
6. Butman JA, Kim HJ, Baggenstos M, Ammerman JM, Dambrosia J, Patsalides A, Patronas NJ, Oldfield EH and Lonser RR. Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA. 2007;298(1):41-48.
7. Wenig BM and Heffner DK. Endolymphatic Sac Tumors:Fact or Fiction? Advances in Anatomic Pathology. 1996; 3(6):378-387.
8. Schick B, Kronsbein H, Kahle G, Prescher A and Draf W. Papillary tumor of the temporal bone. Skull Base. 2001;11(1):25-33.
9. Muller M, Zammit-Maempel I, Hill J and Wilkins B. An unusual middle-ear mass. J Laryngol Otol. 2010;124(1):108-110.
10. Kim HJ, Hagan M, Butman JA, Baggenstos M, Brewer C, Zalewski C, Linehan WM and Lonser RR. Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications. Laryngoscope. 2013;123(2):477-483.
11. Pao W and Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010;10(11):760-774.
12. Sordella R, Bell DW, Haber DA and Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science. 2004;305(5687):1163-1167.
13. Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, 3rd, Regales L, Butaney M, Pao W, Wong KK, Janne PA and Dennis PA. Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M. Cell Rep. 2014;7(6):1824-1832.
14. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA and Pao W. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000-3010.
15. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS and Janne PA. Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462(7276):1070-1074.
16. Perl AK, Tichelaar JW and Whitsett JA. Conditional gene expression in the respiratory epithelium of the mouse. Transgenic Res. 2002;11(1):21-29.
17. Tichelaar JW, Lu W and Whitsett JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem. 2000;275(16):11858-11864.
18. Boggaram V. Regulation of lung surfactant protein gene expression. Front Biosci. 2003;8:d751-764.
19. Dutton JM, Goss K, Khubchandani KR, Shah CD, Smith RJ and Snyder JM. Surfactant protein A in rabbit sinus and middle ear mucosa. Ann Otol Rhinol Laryngol. 1999;108(10):915-924.
20. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, Hirano S, Yoshino T, Takata M, Tanimoto M and Kiura K. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res. 2009;69(17):7088-7095.
21. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16.
22. Yarden Y and Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer. 2012;12(8):553-563.
23. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PO, Eskilsson E, Stieber D, Keunen O, Brekka N, Moen I, Nigro JM, Vintermyr OK, et al. EGFR wildtype amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013;125(5):683-698.
24. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA and Lee S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem. 2003;278(45):44966-44974.
25. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K and Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 2005;65(12):5221-5230.
26. Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR and Ettinger DS. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.
27. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, Miller VA and Pao W. Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations. Cancer Discov. 2014.
28. Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF and Pao W. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One. 2007;2(8):e810.
29. Floyd HS, Farnsworth CL, Kock ND, Mizesko MC, Little JL, Dance ST, Everitt J, Tichelaar J, Whitsett JA and Miller MS. Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas:development of a novel mouse lung tumor model. Carcinogenesis. 2005;26(12):2196-2206.
30. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W and Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006;20(11):1496-1510.
31. Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM and Dennis PA. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget. 2014;5(4):1062-1070.
32. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.